Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

) and cytotoxic T- lymphocyte antigen-4 (CTLA-4), respectively. The current study is designed to evaluate the triple combination of sitravatinib plus NIVO/IPI in patients with solid tumor

nivolumab
VEGFR2
ipilimumab
monoclonal antibodies
tyrosine
  • 27 views
  • 15 Sep, 2020
  • 1 location
Preconditioning of Tumor Tumor Microenvironment and the Immune System to Immunotherapy

, BRAF wildtype melanoma with primary resistance to anti-programmed-cell-death-1 (PD-1/PD-L1) or PD-1 plus anti-cytotoxic-T-lymphocyte antigen 4 (CTLA-4) blockade therapy. If the activity is clinically

  • 0 views
  • 29 Jan, 2021
  • 1 location
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for

western blot
therapeutic agents
spiral computed tomography
cytotoxic therapy
HIV Vaccine
  • 182 views
  • 10 Apr, 2021
  • 35 locations
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Objectives To evaluate the efficacy, in terms of tumor shrinkage, objective response rate, and down-stage rate, of nivolumab + ipilimumab as neoadjuvant therapy for patients with HCC; To evaluate the safety profile in patients with HCC who receive neoadjuvant nivolumab + ipilimumab treatment; To collect HCC tumor tissue and peripheral …

  • 0 views
  • 27 Jan, 2021
  • 8 locations
Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)

Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC). They most often occur during disease progression. It is thought that more than half of the patients with bone metastases will have at least 1 skeletal-related event (SRE, i.e. pathological fractures, medullary compression, analgesic radiotherapy, preventive and/or analgesic surgery and …

squamous cell carcinoma
liver metastasis
epidermal growth factor receptor
ct scan
bisphosphonate
  • 102 views
  • 25 Jan, 2021
  • 43 locations
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies

by loss of function mutations in the LRBA (encoding lipopolysaccharide-responsive beige like anchor protein) and CTLA4 (encoding cytotoxic T lymphocyte antigen 4) genes, which are in common

  • 0 views
  • 25 Jan, 2021
  • 1 location
Open-label Uncontrolled Non-Interventional Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

The recent approval of ICB treatments targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1/PD-L1) by the US Food and Drug Administration has offered an improved

  • 0 views
  • 03 May, 2021
  • 1 location